235 related articles for article (PubMed ID: 31656561)
1. Immunotherapy-related hepatitis: real-world experience from a tertiary centre.
Cheung V; Gupta T; Payne M; Middleton MR; Collier JD; Simmons A; Klenerman P; Brain O; Cobbold JF
Frontline Gastroenterol; 2019 Oct; 10(4):364-371. PubMed ID: 31656561
[TBL] [Abstract][Full Text] [Related]
2. Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors.
De Martin E; Michot JM; Papouin B; Champiat S; Mateus C; Lambotte O; Roche B; Antonini TM; Coilly A; Laghouati S; Robert C; Marabelle A; Guettier C; Samuel D
J Hepatol; 2018 Jun; 68(6):1181-1190. PubMed ID: 29427729
[TBL] [Abstract][Full Text] [Related]
3. Clinicopathological characteristics and management of colitis with anti-PD1 immunotherapy alone or in combination with ipilimumab.
Nahar KJ; Rawson RV; Ahmed T; Tattersall S; Sandanayake N; Kiely CJ; Lo S; Carlino M; Palendira U; Scolyer RA; Long GV; Menzies AM
J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33234603
[TBL] [Abstract][Full Text] [Related]
4. Early Liver Specialist Consultation is Associated With Faster Biochemical Resolution of Severe Immune Checkpoint Inhibitor-Induced Hepatitis.
Li M; Wong D; Sack JS; Vogel AS; Hodi FS; Fong L; Lai JC; Grover S; Zucker SD
J Natl Compr Canc Netw; 2023 Jun; 21(6):617-626.e3. PubMed ID: 37308118
[TBL] [Abstract][Full Text] [Related]
5. Immune Checkpoint Inhibitors-Induced Hepatitis.
Tian Y; Abu-Sbeih H; Wang Y
Adv Exp Med Biol; 2018; 995():159-164. PubMed ID: 30539511
[TBL] [Abstract][Full Text] [Related]
6. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
7. Hepatotoxicity induced by immune checkpoint inhibitors: a comprehensive review including current and alternative management strategies.
Jennings JJ; Mandaliya R; Nakshabandi A; Lewis JH
Expert Opin Drug Metab Toxicol; 2019 Mar; 15(3):231-244. PubMed ID: 30677306
[TBL] [Abstract][Full Text] [Related]
8. Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition.
Heppt MV; Heinzerling L; Kähler KC; Forschner A; Kirchberger MC; Loquai C; Meissner M; Meier F; Terheyden P; Schell B; Herbst R; Göppner D; Kiecker F; Rafei-Shamsabadi D; Haferkamp S; Huber MA; Utikal J; Ziemer M; Bumeder I; Pfeiffer C; Schäd SG; Schmid-Tannwald C; Tietze JK; Eigentler TK; Berking C
Eur J Cancer; 2017 Sep; 82():56-65. PubMed ID: 28648699
[TBL] [Abstract][Full Text] [Related]
9. Severe steroid-resistant anti-PD1 T-cell checkpoint inhibitor-induced hepatotoxicity driven by biliary injury.
Doherty GJ; Duckworth AM; Davies SE; Mells GF; Brais R; Harden SV; Parkinson CA; Corrie PG
ESMO Open; 2017; 2(4):e000268. PubMed ID: 29081991
[TBL] [Abstract][Full Text] [Related]
10. Hepatotoxicity After Immune Checkpoint Inhibitor Therapy in Melanoma: Natural Progression and Management.
Huffman BM; Kottschade LA; Kamath PS; Markovic SN
Am J Clin Oncol; 2018 Aug; 41(8):760-765. PubMed ID: 28749795
[TBL] [Abstract][Full Text] [Related]
11. Thrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapy.
Shiuan E; Beckermann KE; Ozgun A; Kelly C; McKean M; McQuade J; Thompson MA; Puzanov I; Greer JP; Rapisuwon S; Postow M; Davies MA; Eroglu Z; Johnson D
J Immunother Cancer; 2017; 5():8. PubMed ID: 28239462
[TBL] [Abstract][Full Text] [Related]
12. Ipilimumab-induced toxicities and the gastroenterologist.
Cheng R; Cooper A; Kench J; Watson G; Bye W; McNeil C; Shackel N
J Gastroenterol Hepatol; 2015 Apr; 30(4):657-66. PubMed ID: 25641691
[TBL] [Abstract][Full Text] [Related]
13. Compromise or not? A case report of successful treatment of pembrolizumab-induced hepatitis in a patient with non-small cell lung cancer with low-dose methylprednisolone and bicyclol.
Liu Y; Zhang J; Yin Z; Zhu X; Xue L; Cao B
Thorac Cancer; 2020 Jul; 11(7):2023-2030. PubMed ID: 32379397
[TBL] [Abstract][Full Text] [Related]
14. Effect of corticosteroid dosing on outcomes in high-grade immune checkpoint inhibitor hepatitis.
Li M; Wong D; Vogel AS; Sack JS; Rahma OE; Hodi FS; Zucker SD; Grover S
Hepatology; 2022 Mar; 75(3):531-540. PubMed ID: 34709662
[TBL] [Abstract][Full Text] [Related]
15. PD-L1 expressing granulomatous reaction as an on-target mechanism of steroid-refractory immune hepatotoxicity.
Black JR; Goldin RD; Foxton M; Marafioti T; Akarca AU; Pria AD; Brock C; Bower M; Pinato DJ
Immunotherapy; 2019 May; 11(7):585-590. PubMed ID: 30943859
[TBL] [Abstract][Full Text] [Related]
16. Liver toxicity as a limiting factor to the increasing use of immune checkpoint inhibitors.
De Martin E; Michot JM; Rosmorduc O; Guettier C; Samuel D
JHEP Rep; 2020 Dec; 2(6):100170. PubMed ID: 33205034
[TBL] [Abstract][Full Text] [Related]
17. Metastatic uveal melanoma showing durable response to anti-CTLA-4 and anti-PD-1 combination therapy after experiencing progression on anti-PD-1 therapy alone.
Afzal MZ; Mabaera R; Shirai K
J Immunother Cancer; 2018 Feb; 6(1):13. PubMed ID: 29433557
[TBL] [Abstract][Full Text] [Related]
18. Real-world efficacy and toxicity of combined nivolumab and ipilimumab in patients with metastatic melanoma.
Parakh S; Randhawa M; Nguyen B; Warburton L; Hussain MA; Cebon J; Millward M; Yip D; Ali S
Asia Pac J Clin Oncol; 2019 Feb; 15(1):26-30. PubMed ID: 30426665
[TBL] [Abstract][Full Text] [Related]
19. Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of severe gastrointestinal and hepatic toxicities from checkpoint inhibitors.
Dougan M; Blidner AG; Choi J; Cooksley T; Glezerman I; Ginex P; Girotra M; Gupta D; Johnson D; Shannon VR; Suarez-Almazor M; Anderson R; Rapoport BL
Support Care Cancer; 2020 Dec; 28(12):6129-6143. PubMed ID: 32856210
[TBL] [Abstract][Full Text] [Related]
20. Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study.
Pires da Silva I; Ahmed T; Reijers ILM; Weppler AM; Betof Warner A; Patrinely JR; Serra-Bellver P; Allayous C; Mangana J; Nguyen K; Zimmer L; Trojaniello C; Stout D; Lyle M; Klein O; Gerard CL; Michielin O; Haydon A; Ascierto PA; Carlino MS; Lebbe C; Lorigan P; Johnson DB; Sandhu S; Lo SN; Blank CU; Menzies AM; Long GV
Lancet Oncol; 2021 Jun; 22(6):836-847. PubMed ID: 33989557
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
